NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 2,623 shares of the business's stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $14.06, for a total value of $36,879.38. Following the completion of the sale, the insider now directly owns 3,501,975 shares of the company's stock, valued at $49,237,768.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Tuesday, April 16th, Orbimed Advisors Llc sold 14,069 shares of NeuroPace stock. The shares were sold at an average price of $14.01, for a total value of $197,106.69.
- On Thursday, April 11th, Orbimed Advisors Llc sold 461,899 shares of NeuroPace stock. The shares were sold at an average price of $14.49, for a total value of $6,692,916.51.
NeuroPace Trading Up 1.8 %
NPCE stock opened at $14.00 on Friday. The stock's fifty day simple moving average is $14.53 and its 200-day simple moving average is $11.36. The company has a debt-to-equity ratio of 2.76, a quick ratio of 5.02 and a current ratio of 5.71. NeuroPace, Inc. has a 52-week low of $3.80 and a 52-week high of $18.15.
READ THIS – If You Missed Out On The AI Boom
From Banyan Hill Publishing | Ad
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy.
Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Click on Adam's shiny forehead for more details.
NeuroPace (NASDAQ:NPCE - Get Free Report) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.10. NeuroPace had a negative return on equity of 153.76% and a negative net margin of 50.38%. The company had revenue of $18.01 million for the quarter, compared to analyst estimates of $17.74 million. Equities analysts predict that NeuroPace, Inc. will post -1.14 EPS for the current year.
Analyst Ratings Changes
Several analysts have commented on NPCE shares. Morgan Stanley upped their price objective on NeuroPace from $9.00 to $13.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 6th. SVB Leerink assumed coverage on NeuroPace in a research note on Tuesday, January 30th. They set an "outperform" rating and a $22.00 target price for the company. Cantor Fitzgerald increased their target price on NeuroPace from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 6th. Leerink Partnrs reissued an "outperform" rating on shares of NeuroPace in a research note on Tuesday, January 30th. Finally, Lake Street Capital reissued a "buy" rating and set a $12.00 target price on shares of NeuroPace in a research note on Wednesday, December 27th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $15.67.
View Our Latest Stock Analysis on NPCE
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its stake in shares of NeuroPace by 2.1% during the first quarter. State Street Corp now owns 98,717 shares of the company's stock valued at $810,000 after acquiring an additional 2,042 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of NeuroPace by 19.3% during the second quarter. Renaissance Technologies LLC now owns 17,300 shares of the company's stock valued at $78,000 after acquiring an additional 2,800 shares in the last quarter. Citigroup Inc. acquired a new stake in shares of NeuroPace during the third quarter valued at about $29,000. Barclays PLC grew its stake in shares of NeuroPace by 28.9% during the fourth quarter. Barclays PLC now owns 13,971 shares of the company's stock valued at $144,000 after acquiring an additional 3,132 shares in the last quarter. Finally, BlackRock Inc. grew its stake in shares of NeuroPace by 11.2% during the second quarter. BlackRock Inc. now owns 36,117 shares of the company's stock valued at $162,000 after acquiring an additional 3,646 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
